Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment

Abstract

Malignant pleural mesothelioma (MPM) is the most common primary malignancy of the pleura. The occurrence of malignant mesothelioma is typically related to exposure to mineral fibers such as asbestos and erionite.[1‐3] Reports suggest that genetic factors may also play a role in MPM.[4] Moreover, latency periods that are the period of time between the first exposure to asbestos and a disease diagnosis range from 20 to 50 years. The mortality burden from asbestos‐related diseases (ARD) is heavy and ARD accounts for 92,250 deaths per year globally.[5] To improve survival of MPM patients, effective strategy of early diagnosis and effective treatment strategies are highly needed.

DOI: 10.4103/0366-6999.196585

Cite this paper

@inproceedings{Ban2017ImprovementOM, title={Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment}, author={Cheng-jun Ban and Huan-zhong Shi and Yu-hui Zhang}, booktitle={Chinese medical journal}, year={2017} }